Looking Ahead to 2024: Robust Outlook for Specialty Drugs, Cell and Gene Therapies
Significant industry trends worth watching in the new year.
AscellaHealth
From Development to Access: Overcoming the Challenges of Clinical Trials for Specialty Drugs, Cell & Gene Therapies
The challenges of clinical trials for patients with rare and orphan diseases.
Advances in Hemophilia Treatment
New developments and therapies for the treatment for Hemophilia.
Breaking Ground in NASH Treatment: Resmetirom on the Horizon
Development in treatment for patients with non-alcoholic steatohepatitis (NASH).
Update on Regulatory Review of Gene Therapy for Duchenne Muscular Dystrophy
Patients and families with Duchenne Muscular Dystrophy (DMD) await regulatory action.
Spinal Cord Injuries: The Impacts, Current and Future Treatments
Looking at treatments with the potential to enhance outcomes for those suffering from spinal cord injuries.
FDA Approves First Gene Therapy for Rare Skin Disorder, Offering New Hope for Wound Healing in Dystrophic Epidermolysis Bullosa (DEB)
Vyjuvek™ (beremagene geperpavec), a topical gene therapy for the relief of a rare genetic skin disorder.
Pharmaceutical Companies Turn to AscellaHealth for Consultative Business Model, Including Robust Pre-Commercialization and Market Access Services
Specialty drug manufacturers are seeking innovative approaches to effectively launch new products.
Pursuing A New Paradigm in Inclusive Research
The significance of clinical trials to provide more robust data, ultimately leading to more effective medicines for patients who need them.
End-to-End Solutions Optimize Rare Disease Clinical Trials and Product Commercialization
Pharmaceutical manufacturers rely upon AscellaHealth as a single resource for managing all phases of rare disease clinical trials.
A Look at von Willebrand Disease
An inherited blood clotting disorder caused by either a deficiency or a dysfunction of the von Willebrand factor (vWf) protein.
HUB & Patient Support Solutions Complement Pre-Commercialization Services
AscellaHealth’s expanded HUB/ Patient Support Services for Life Sciences manufacturers are recognized as the best-in-class outsourced solutions for successful medication access, compliance and persistency and enhanced outcomes.
Re-Think. Re-Consider. Re-Calibrate.
2023 Go-to-Market Strategies for Launching Specialty Drugs, Gene & Cell Therapies
Something for Everyone at Rare Disease Week on Capitol Hill
Rare Disease Week on Capitol Hill, February 28th through March 2nd, 2023.
AscellaHealth EU
AscellaHealth Specialty Pharmacy Distribution & Market Access Webinar Highlights
Experts provide in-depth insights on commercialization strategy, distribution models and demonstrating therapeutic value of Rare Disease & Gene/Cell therapies for patients, payers, and providers.
AscellaHealth Family of Companies Announces Founding Sponsorship: Gene Therapy and Specialty Pharmacy Awareness Month
September 2022: Join us in recognizing industry innovations
Global Genes: Improving the Path to Diagnosis and Treatment for Individuals Living with Rare Disease
With more than 10,000 rare diseases, Global Genes focuses on advancing innovation and overcoming challenges.
Changing the Face of Market Access and Commercialization
AscellaHealth Family of Companies brings integrated, customized approach for specialty drugs underscoring value of effective payer strategies.
Patient-First Approach: Initial Step in Addressing Nation’s Health Inequities
Removing barriers to reach Health equity.
Optimizing Treatment for Rare Genetic Condition: Cushing’s Syndrome
Cushing’s syndrome, a rare endocrine disorder and FDA approved treatments.
Update on Gene Therapy and Genome-Editing for Rare Diseases
There’s some upbeat news in gene therapy and genome-editing treatments.
Pharmaceutical Companies Turn to AscellaHealth Family of Companies for Consultative Business Model, Including Robust Pre-Commercialization and Market Access Services
Foundation for the National Institutes of Health Accelerates Biomedical Research and Strategies Around the World
FNIH manages alliances with public and private institutions in support of the mission of the National Institutes of Health (NIH).
Patient Services and Hub Solutions for Life Sciences: Ensuring Specialty Product Access and Market Entry, Optimizing Outcomes for Rare Disease Patients
The rare disease community is gaining attention around the world, shining a light on the challenges and barriers to accessing care.